-
CAS:718613-28-6|Irinotecan-d10，(+-Irinotecan-d10; CPT-11-d10; VAL-413-d10
作者：德尔塔生物 日期：2025-07-08
生物活性：Irinotecan-d10 is a deuterium labeled Irinotecan ((+)-Irinotecan). Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex[1].分子量：596.74Formula：C33H28D10N4O6CAS 号：718613-28-6非标记 CAS：97682-44-5性状：固体颜色：White to off-white中文名称：伊立替康 d10运输条件：Room temperature in continental US; may vary elsewhere.储存方式：4°C, protect from light*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)纯度 & 产品资料Data Sheet (523 KB)产品使用指南 (1538 KB)参考文献[1]. Morales C, et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb;56(3):219-26. [Content Brief]
-
CAS:1807367-80-1|Minodronic acid-d4，YM-529-d4
作者：德尔塔生物 日期：2025-07-08
生物活性：Minodronic acid-d4 is deuterium labeled Minodronic acid. Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain[1][2].IC50 & Target：P2X2 ReceptorP2X3 Receptor体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Minodronic acid-d4 相关抗体:ERK1/2 AntibodyE-Cadherin Antibody (YA470)Fatty Acid Synthase Antibody (YA766)DYKDDDDK Tag (FLAG) AntibodyGAPDH AntibodyGFP Antibodyp53 Antibody (YA250)RUNX2 AntibodyFerritin Heavy Chain AntibodyCOX2 AntibodyCtip2 AntibodyCyclin D1 Antibody (YA485)Cytochrome C Antibodyc-Myc AntibodyCyclin E1 AntibodyAIF Antibody (YA636)ALIX AntibodyCNPase AntibodyCortactin AntibodyCOX IV AntibodyCOX2/Cyclooxygenase 2 AntibodyCyclin A2 AntibodyCyclin B1 Antibody (YA486)DR5 AntibodyDrosha AntibodyE-Cadherin Antibody (YA778)EEA1 AntibodyEpCAM Antibody (YA772)Fatty Acid Synthase AntibodyFIP200 Antibody分子量：326.17Formula：C9H8D4N2O7P2CAS 号：1807367-80-1非标记 CAS：180064-38-4中文名称：米诺磷酸-d4运输条件：Room temperature in continental US; may vary elsewhere.
-
CAS:2300178-72-5|Kevetrin hydrochloride-13C2,15N3
作者：德尔塔生物 日期：2025-07-08
生物活性：Kevetrin (hydrochloride)-13C2,15N3 is the 13C-labeled and 15N-labeled Kevetrin (hydrochloride). Kevetrin hydrochloride is a small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity.体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Kevetrin hydrochloride-13C2,15N3 相关抗体:p53 Antibodyp53 Antibody (YA250)p21 Antibody (YA254)p21 AntibodyFOXO4 Antibodyp53 (acetyl K382) Antibodyp53 DINP1 Antibodyp53 (acetyl K370)AntibodyPhospho-p53 (Ser392) AntibodyAcetyl-p53 (Lys370) AntibodyPhospho-p53 (Ser37) AntibodyPhospho-p53 (Ser6) AntibodyPERP Antibody (YA1674)p73 Antibody (YA1240)PEPD Antibody (YA1578)Phospho-MDM2 (Ser166) Antibody (YA1888)IFRD1 Antibody (YA2507)TP53BP2 Antibody (YA2576)分子量：184.64Formula：C313C2H10Cl15N3SCAS 号：2300178-72-5非标记 CAS：66592-89-0运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (522 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
-
CAS:864933-71-1|ONPG-13C，2-Nitrophenyl β-D-galactopyranoside-13C
作者：德尔塔生物 日期：2025-07-08
生物活性：ONPG-13C is the 13C labeled ONPG. ONPG is a colorimetric and spectrophotometric substrate for detection of β-galactosidase activit[1][2].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：302.24Formula：C1113CH15NO8CAS 号：864933-71-1非标记 CAS：369-07-3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (531 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief][2]. Zhang X, et al. Metagenomic approach for the isolation of a thermostable β-galactosidase with high tolerance of galactose and glucose from soil samples of Turpan Basin. BMC Microbiol. 2013 Oct 24;13:237. doi: 10.1186/1471-2180-13-237. [Content Brief]
-
CAS:2050041-12-6|Ledipasvir-d6，GS-5885-d6
作者：德尔塔生物 日期：2025-07-08
生物活性：Ledipasvir-d6 is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM[3].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Ledipasvir-d6 相关抗体:Cyclophilin A AntibodyCyclophilin B Antibody (YA787)分子量：895.04Formula：C49H48D6F2N8O6CAS 号：2050041-12-6非标记 CAS：1256388-51-8性状：固体颜色：Light yellow to yellow中文名称：雷迪帕韦 d6运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Powder：-20°C：3 years，4°C：2 yearsIn solvent：-80°C：6 months，-20°C：1 month
-
CAS:1298086-22-2|Ertugliflozin-d5，PF-04971729-d5
作者：德尔塔生物 日期：2025-07-08
生物活性：Ertugliflozin-d5 is the deuterium labeled Ertugliflozin[1]. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2[2]. Has the potential for the treatment of type 2 diabetes mellitus[3].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：441.91Formula：C22H20D5ClO7CAS 号：1298086-22-2非标记 CAS：1210344-57-2中文名称：埃格列净-d5运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (538 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief][2]. Mascitti V, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem. 2011 Apr 28;54(8):2952-60. [Content Brief][3]. Miao Z, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Dru
-
CAS:1189992-00-4|Roflumilast-d3，罗氟司特-d3; APTA-2217-d3; BYK 20869-d3; B9302-107-d3
作者：德尔塔生物 日期：2025-07-08
生物活性：Roflumilast-d3 is deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Roflumilast-d3 相关抗体:Acetyl CoA synthetase AntibodyPDE1B Antibody (YA1553)PDE4B Antibody (YA2932)PDE2A Antibody (YA2989)PDE4D Antibody (YA1714)分子量：406.23Formula：C17H11D3Cl2F2N2O3CAS 号：1189992-00-4非标记 CAS：162401-32-3中文名称：罗氟司特-d3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (531 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Hatzelmann A, et al. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010 Aug;23(4):235-56. [Content Brief][3]. Rabe KF. Update on roflumilast, a phosp
-
CAS:1398065-69-4|Roflumilast-d4，APTA-2217-d4; BYK 20869-d4; B9302-107-d4
作者：德尔塔生物 日期：2025-07-08
生物活性：Roflumilast-d4 is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells[1][2].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Roflumilast-d4 相关抗体:Acetyl CoA synthetase AntibodyPDE1B Antibody (YA1553)PDE4B Antibody (YA2932)PDE2A Antibody (YA2989)PDE4D Antibody (YA1714)分子量：407.23Formula：C17H10D4Cl2F2N2O3CAS 号：1398065-69-4非标记 CAS：162401-32-3中文名称：罗氟司特 d4运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (527 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Hatzelmann A, et al. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010 Aug;23(4):235-56. [Content Brief][3]. Rabe KF. Update on roflumilas
-
CAS:2748267-73-2|Etoricoxib-13C,d3，依托考昔-13C,d3; MK-0663-13C,d3; L-791456-13C,d3
作者：德尔塔生物 日期：2025-07-08
生物活性：Etoricoxib-13C,d3 is the 13C- and deuterium labeled Etoricoxib. Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[66].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Etoricoxib-13C,d3 相关抗体:COX2 AntibodyCOX IV AntibodyCOX2/Cyclooxygenase 2 AntibodyCOX IV Antibody (YA867)Cyclooxygenase 1 Antibody (YA2537)Cyclooxygenase 2 Antibody (YA2541)分子量：362.85Formula：C1713CH12D3ClN2O2SCAS 号：2748267-73-2非标记 CAS：202409-33-4中文名称：依托考昔-13C,d3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (531 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [Content Brief][2]. Riendeau D, et al.Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther. 2001 Feb;296(2):558-66. [Content Brief][3]. Kunak CS, et al. The Effect of Et
-
CAS:1564241-79-7|Baricitinib-d5，LY3009104-d5; INCB028050-d5
作者：德尔塔生物 日期：2025-07-08
生物活性：Baricitinib-d5 is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Baricitinib-d5 相关抗体:Phospho-JAK2 (Tyr1007/1008) AntibodyJAK1 Antibody (YA722)JAK1 AntibodyJAK2 Antibody (YA721)Phospho-JAK2 (Tyr1007+Tyr1008) AntibodyJAK2 Antibody (YA330)Phospho-JNK (Thr183) AntibodyJAK3 Antibody (YA2466)分子量：376.45Formula：C16H12D5N7O2SCAS 号：1564241-79-7非标记 CAS：1187594-09-7中文名称：巴瑞克替尼 d5运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (533 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Fridman JS, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010 May 1;184(9):5298-307. [Content Brief][3]. Jabbari A, et al. Reversal of Alopecia Areata
-
CAS:1216551-07-3|3-Methyl Hippuric acid-d7
作者：德尔塔生物 日期：2025-07-08
生物活性：3-Methyl Hippuric acid-d7 is the deuterium labeled 3-Methyl Hippuric acid[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：200.24Formula：C10H4D7NO3CAS 号：1216551-07-3非标记 CAS：27115-49-7性状：固体颜色：White to off-white运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Powder：-20°C：3 years，4°C：2 yearsIn solvent：-80°C：6 months，-20°C：1 month纯度 & 产品资料纯度： 99%参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
-
CAS:1353940-55-2|Brombuterol-d9，Bromobuterol d9
作者：德尔塔生物 日期：2025-07-08
生物活性：Brombuterol-d9 is a deuterium labeled Brombuterol. Brombuterol is a β-adrenergic receptor agonist[1].IC50 & Target：β adrenergic receptor分子量：375.15Formula：C12H9D9Br2N2OCAS 号：1353940-55-2性状：固体颜色：White to off-white中文名称：溴布特罗 d9运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Powder：-20°C：3 years，4°C：2 yearsIn solvent：-80°C：6 months，-20°C：1 month纯度 & 产品资料纯度： ≥99.0%参考文献[1]. E Sangiorgi, et al. Application of a Sequential Analytical Procedure for the Detection of the Beta-Agonist Brombuterol in Bovine Urine Samples. J Chromatogr B Biomed Sci Appl. 1997 Jun 6;693(2):468-78. [Content Brief]
-
CAS:2699607-19-5|(±11(12-EET-d11，(±11,12-EET-d11
作者：德尔塔生物 日期：2025-07-08
生物活性：(±)11(12)-EET-d11 is the deuterium labeled (±)11(12)-EET. (±)11(12)-EET is a NLRP3 inflammasome inhibitor. (±)11(12)-EET can be used for the research of anti-inflammatory, angiogenic and cardioprotective[1][2][3][4][6].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.(±)11(12)-EET-d11 相关抗体:NLRP3 AntibodyNLRP3 AntibodyASC Antibody分子量：331.53Formula：C20H21D11O3CAS 号：2699607-19-5非标记 CAS：87173-81-7性状：液体颜色：Colorless to light yellow运输条件：Room temperature in continental US; may vary elsewhere.储存方式：-20°C, sealed storage, away from moisture*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)纯度 & 产品资料纯度： 98.0%参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Luo XQ, et al. Epoxyeicosatrienoic acids inhibit the activation of NLRP3 inflammasome in murine macrophages. J Cell Physiol. 2020;235(12):9910-9921. [Content Brief][3]. Chacos N, et al. Novel epoxides formed during the liver cytochrome P-450 oxidation of arachidonic acid. Biochem Biophys Res Commun. 1982;104(3):916-922. [Content Brief][4]. Oliw EH, et al. Oxygenation
-
CAS:1830330-31-8|Idelalisib-d5，CAL-101 d5; GS-1101 d5
作者：德尔塔生物 日期：2025-07-08
生物活性：Idelalisib-d5 is a deuterium labeled Idelalisib. Idelalisib is a highly selective and orally bioavailable p110δ inhibitor[1].IC50 & Target：P110δ inhibitor分子量：420.45Formula：C22H13D5FN7OCAS 号：1830330-31-8非标记 CAS：870281-82-6性状：固体颜色：White to off-white中文名称：艾代拉里斯 d5运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Powder：-20°C：3 years，4°C：2 yearsIn solvent：-80°C：6 months，-20°C：1 month
-
CAS:1413431-05-6|Ivacaftor-d18，依伐卡托-d18; VX-770-d18
作者：德尔塔生物 日期：2025-07-08
生物活性：Ivacaftor-d18 is the deuterium labeled Ivacaftor[1]. Ivacaftor (VX-770) is a potent and orally bioavailable CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC50s of 100 nM and 25 nM, respectively[2].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Ivacaftor-d18 相关抗体:Calumenin Antibody (YA813)分子量：410.60Formula：C24H10D18N2O3CAS 号：1413431-05-6非标记 CAS：873054-44-5性状：固体颜色：White to off-white中文名称：依伐卡托-d18运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Powder：-20°C：3 years，4°C：2 yearsIn solvent：-80°C：6 months，-20°C：1 month纯度 & 产品资料纯度： 92.92%参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief][2]. Delaunay JL, et al. Functional defect of variants in the adenosine triphosphate-binding sites of ABCB4 and their rescue by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor (VX-770). Hepatology. 2017 Feb;65(2):560-570. [Content Brief]
咨询热线
18133906270
德尔塔官方微信